Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
fulvestrant+lapatinib
- Development stage
- Phase 3
- Lead developer
- GSK
- Modality
- Small Molecules
- Administration
- Intramuscular, Oral
01
Overview
Fulvestrant + lapatinib is a combination therapy for advanced or metastatic estrogen receptor (ER)-positive breast cancer. Fulvestrant is a selective estrogen receptor degrader (SERD) that binds to and degrades the ER, while lapatinib is a small molecule tyrosine kinase inhibitor targeting both epidermal growth factor receptor (EGFR/HER1) and human epidermal growth factor receptor 2 (HER2/ERBB2). The combination was investigated in clinical trials to determine if adding lapatinib to fulvestrant would improve outcomes in patients with hormone receptor-positive breast cancer, but results showed no significant improvement in progression-free survival or overall survival compared to fulvestrant alone, with increased toxicity associated with the addition of lapatinib[1][6].
- Other names
- fulvestrant and lapatiniblapatinib plus fulvestrant
02
Targets
Beyond the preview
Go deeper on fulvestrant+lapatinib.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on fulvestrant+lapatinib.